



Roche

Starting the path towards a diagnosis of Alzheimer's disease requires action. And it all begins with a spark.

Introducing the Elecsys[®] Phospho-Tau (181P) CSF and β -Amyloid (1-42) CSF II assays.

Designed to quantify levels of key biomarkers reliably and precisely, the Elecsys[®] Phospho-Tau (181) CSF/Elecsys[®] β -Amyloid (1-42) CSF II ratio demonstrates a **90% concordance with β -Amyloid positron emission tomography (PET) scan results.**¹

Detecting a patient's Alzheimer's disease (AD) early may enable timely interventions that alleviate symptoms, helping preserve their 'spark' longer. Results from Elecsys[®] AD CSF assays aid in clinical decisions.¹



References:

1. Elecsys[®] Method Sheet: ms_08846693501, ms_08846715501, ms_08821909501, ms_08821941501.

A positive pTau181/Abeta42 ratio result in CSF does not establish a diagnosis of Alzheimer's disease (AD) and should always be interpreted in conjunction with clinical information.

Photos do not depict actual patients